Certara (CERT) delivered earnings and revenue surprises of +12.50% and +2.93%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Certara (CERT) delivered earnings and revenue surprises of +12.50% and +2.93%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -4.00% and +23.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) delivered earnings and revenue surprises of +11.11% and +13.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -85.71% and +7.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Precigen (PGEN) delivered earnings and revenue surprises of +20.00% and +9.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The only curated source of news from smaller, under-the-radar stocks in the hottest sectors ready to make a move, and the analysis and rumors from social media driving the price action.
Innovation is the lifeblood of the MedTech sector. Literally. Discoveries made are more than value drivers for the companies behind them; they can be life savers to millions needing better and more effective healthcare solutions.